C4 Therapeutics (NASDAQ:CCCC – Get Rating) had its price objective lowered by Bank of America from $11.00 to $5.00 in a research report released on Tuesday morning, The Fly reports. Bank of America currently has a neutral rating on the stock. CCCC has been the subject of several other research reports. JPMorgan Chase & Co. […]
Nisa Investment Advisors LLC raised its stake in shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) by 893.8% during the 3rd quarter, Holdings Channel.com reports. The fund owned 6,460 shares of the biotechnology company’s stock after purchasing an additional 5,810 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Atara Biotherapeutics were worth […]
Ebvallo™ EU Launch Activities Led by Pierre Fabre to Commence in Q1 2023Discussions with FDA Progressing on Potential U.S. BLA for Tab-cel®ATA188 Phase 2 EMBOLD Study Primary Data Readout On-Track for October 2023Cash Runway Extended into Q2 2024THOUSAND OAKS, Calif. (BUSINESS WIRE) $ATRA #CART Atara Biotherapeut.
Creative Planning grew its stake in Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) by 10.5% in the 3rd quarter, Holdings Channel reports. The firm owned 67,118 shares of the biotechnology company’s stock after purchasing an additional 6,390 shares during the period. Creative Planning’s holdings in Atara Biotherapeutics were worth $254,000 at the end of the […]